Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer's risk: a drug-target Mendelian randomization study
- PMID: 40597970
- PMCID: PMC12211516
- DOI: 10.1186/s12885-025-14350-2
Genetically proxied therapeutic effect of antihypertensive drug use, breast cancer, and ovarian cancer's risk: a drug-target Mendelian randomization study
Abstract
Background: Observational studies have explored the association between antihypertensive drugs and the risk of breast cancer (BC) and ovarian cancer (OC). However, some controversy persists.
Objective: Our study aims to investigate the causal relationship between genetic proxies for antihypertensive drugs and breast and ovarian cancers using two-sample Mendelian randomization (MR) analysis.
Methods: Analyses were primarily conducted using the inverse variance weighted (IVW) method, with heterogeneity and horizontal pleiotropy tests, as well as sensitivity analysis, to assess the robustness of the results and the strength of the causal relationship.
Results: Using the Bonferroni-corrected P-value as the threshold for testing causality (P < 0.0025), the MR analysis of systolic blood pressure as a biomarker in subset (A) (OR = 1.059, 95% CI: 1.024-1.096, P = 9.581 × 10- 4) and subset (B) (OR = 1.000, 95% CI: 1.000-1.001, P = 6.726 × 10- 4) both found that genetically predicted calcium channel blockers (CCBs) increased the risk of ovarian cancer. The same result was found only in subset (B) in the MR analysis of diastolic blood pressure as a biomarker (OR = 1.001, 95% CI: 1.000-1.001, P = 3.465 × 10- 4), while subset (A) showed a suggestive association between CCBs and the risk of ovarian cancer development (OR = 1.088, 95% CI: 1.027-1.153, P = 0.004). Neither heterogeneity nor horizontal pleiotropy was detected, and no evidence of an association between other antihypertensive drugs and breast or ovarian cancer was found.
Conclusions: Our study provides genetic evidence that CCBs increase the risk of OC, offering insight into the potential risks of pharmacological treatment with CCBs.
Keywords: Antihypertensive drugs; Breast cancer; Drug-Target MR; Mendelian randomization; Ovarian cancer.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: Not applicable. Competing interests: The authors declare no competing interests.
Figures
Similar articles
-
Causal association between telomere length and female cancers: a two-sample Mendelian randomization study.Postgrad Med J. 2025 Aug 17;101(1199):863-872. doi: 10.1093/postmj/qgaf028. Postgrad Med J. 2025. PMID: 39964064
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 Aug 15;(8):CD002003. doi: 10.1002/14651858.CD002003.pub3. PMID: 17253471 Updated.
-
Increased risk of hypertrophic scarring in estrogen receptor-positive breast cancer: a bidirectional mendelian randomization study.Arch Dermatol Res. 2025 Jan 20;317(1):299. doi: 10.1007/s00403-024-03737-z. Arch Dermatol Res. 2025. PMID: 39833481
-
Beta-blockers for hypertension.Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5. Cochrane Database Syst Rev. 2017. PMID: 28107561 Free PMC article.
-
Association of antihypertensive drug target genes with alzheimer's disease: a mendelian randomization study.Alzheimers Res Ther. 2025 Jan 10;17(1):18. doi: 10.1186/s13195-025-01671-4. Alzheimers Res Ther. 2025. PMID: 39794838 Free PMC article.
References
-
- Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–50. 10.1016/S0140-6736(16)31891-8. - PubMed
-
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. 10.3322/caac.21660. - PubMed
-
- American Cancer Society. Cancer Facts & Figs. 2024. Atlanta: American Cancer Society; 2024.
-
- Kidoguchi S, Sugano N, Tokudome G, Yokoo T, Yano Y, Hatake K, et al. New concept of Onco-Hypertension and future perspectives. Hypertension. 2021;77:16–27. 10.1161/HYPERTENSIONAHA.120.16044. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical